After a median follow-up of 70 months ( IQR 52-91 ) , 5-year event-free survival was better in the augmented treatment group ( 896 % [ 95 % CI 859-933 ] ) than in the standard group ( 828 % [ 781-875 ] ; odds ratio [ OR ] 061 [ 95 % CI 039-098 ] , p = 004 ) .